摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

反式-1-己烯-1-基硼酸 | 42599-18-8

中文名称
反式-1-己烯-1-基硼酸
中文别名
(E)-己烯-1-基硼酸;E-己烯-1-基硼酸
英文名称
(E)-1-hexenylboronic acid
英文别名
(E)-1-hexenyldihydroxyborane;(E)-hex-1-en-1-ylboronic acid;E-Hexen-1-ylboronic acid;[(E)-hex-1-enyl]boronic acid
反式-1-己烯-1-基硼酸化学式
CAS
42599-18-8
化学式
C6H13BO2
mdl
——
分子量
127.979
InChiKey
GWFKSQSXNUNYAC-AATRIKPKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    62-63°C
  • 沸点:
    227.8±23.0 °C(Predicted)
  • 密度:
    0.926±0.06 g/cm3(Predicted)
  • 稳定性/保质期:
    遵照规定使用和储存,则不会分解。

计算性质

  • 辛醇/水分配系数(LogP):
    0.74
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    40.5
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 危险类别码:
    R36/37/38
  • 安全说明:
    S26,S36/37/39
  • 储存条件:
    保持贮藏器密封,并将其放入一个紧密封装的容器中。储存在阴凉、干燥的地方。

SDS

SDS:f1e4f835407803280b5192f05cb6b430
查看
Material Safety Data Sheet

Section 1. Identification of the substance
E-Hexen-1-ylboronic acid
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
E-Hexen-1-ylboronic acid
Ingredient name:
CAS number: 42599-18-8

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H13BO2
Molecular weight: 128.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Palladium-catalyzed conjugated diene synthesis from vinylic halides and olefinic compounds
    摘要:
    DOI:
    10.1021/jo00896a020
  • 作为产物:
    描述:
    1-己炔儿萘酚硼烷 作用下, 以 四氢呋喃 为溶剂, 以100%的产率得到反式-1-己烯-1-基硼酸
    参考文献:
    名称:
    6,7-二取代的4-氨基吡啶并[2,3-d]嘧啶作为腺苷激酶抑制剂的合成及生物学评价。
    摘要:
    描述了一系列6,7-二取代的4-氨基吡啶并[2,3-d]嘧啶作为新型的非核苷腺苷激酶抑制剂的合成与构效关系。发现在吡啶并嘧啶核的C6和C7位上的各种取代基,主要是芳基,可产生作为腺苷激酶的有效抑制剂的类似物。与5,7-二取代和5,6,7-三取代的嘧啶嘧啶系列相反,这些类似物仅表现出适度的能力来抑制完整细胞中的AK。
    DOI:
    10.1016/j.bmcl.2005.03.098
点击查看最新优质反应信息

文献信息

  • Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
    申请人:Palani Anandan
    公开号:US20060264489A1
    公开(公告)日:2006-11-23
    A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.
    具有通式(I)的一种化合物: 或其药学上可接受的盐、溶剂化合物、酯或互变异构体,其中: Q选自以下群组: 和 L选自以下群组: 或其药学上可接受的盐、溶剂化合物、酯或互变异构体,可用于治疗代谢综合征和血脂异常等疾病、疾患或症状。
  • Ligand‐Controlled Regiodivergence in Nickel‐Catalyzed Hydroarylation and Hydroalkenylation of Alkenyl Carboxylic Acids**
    作者:Zi‐Qi Li、Yue Fu、Ruohan Deng、Van T. Tran、Yang Gao、Peng Liu、Keary M. Engle
    DOI:10.1002/anie.202010840
    日期:2020.12.14
    the ligand environment around the metal center dictates the regiochemical outcome. Markovnikov hydrofunctionalization products are obtained under mild ligand‐free conditions, with up to 99 % yield and >20:1 selectivity. Alternatively, anti‐Markovnikov products can be accessed with a novel 4,4‐disubstituted Pyrox ligand in excellent yield and >20:1 selectivity. Both electronic and steric effects on the
    据报道,镍催化的未活化链烯基羧酸的区域发散性氢芳基化和氢烯基化,从而金属中心周围的配体环境决定了区域化学结果。Markovnikov加氢官能化产物是在无配体的温和条件下获得的,产率高达99%,选择性> 20:1。另外,可以使用新型的4,4-二取代的Pyrox配体获得抗Markovnikov产物,并具有优异的收率和> 20:1的选择性。对配体的电子和空间效应都有助于高产率和选择性。机理研究表明,最佳配体引起的营业额限制和选择性决定步骤发生了变化。DFT计算表明,在反马尔科夫尼科夫途径中,
  • Macrocyclic MCL-1 inhibitors and methods of use
    申请人:AbbVie Inc.
    公开号:US20190055264A1
    公开(公告)日:2019-02-21
    The present disclosure provides for compounds of Formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    本公开提供了Formula (I)的化合物,其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值,以及其药学上可接受的盐,可用作治疗疾病和病况的药物,包括癌症。还提供了包含Formula (I)化合物的药物组合物。
  • PRACTICAL PROCEDURE FOR THE PREPARATION OF FUNCTIONALIZED (<i>E</i>)-1-ALKENYLBORONIC ACIDS INCLUDING THE UNPRECEDENTED 1-ALKOXYCARBONYL DERIVATIVES
    作者:Michel Gravel、Barry B. Touré、Dennis G. Hall
    DOI:10.1080/00304940409355974
    日期:2004.12
    the corresponding terminal alkynes. However, the most common methods used for this purpose suffer from chemoand regioselectivity problems. For example, catecholborane? which constitutes the reagent of choice to effect these transformations, does not tolerate aced or ether functionalities at the propargylic Moreover, hydrolysis of the boronate following catecholboration yields an equimolar amount of
    近年来,硼酸在有机合成中具有重要意义。这些化合物的合成应用包括 Suzuki-Miyaura 交叉偶联反应,铑催化加成到醛 2 和丙二烯上,〜二乙酸铜促进的涉及胺、醇的交叉偶联反应,以及 thi〜ls,〜作为以及硼-曼尼希反应。6 两种芳基烯基硼酸都可以参与这些反应;然而,烯基硼酸的分离带来的挑战极大地阻碍了它们的使用。事实上,大多数烯基硼酸在常规纯化条件下是不稳定的,它们相应的酯类虽然稳定,但不适合某些合成应用。~~ 作为我们正在进行的关于不饱和硼酸在有机合成中应用的计划的一部分?我们开始对开发一种方便且通用的制备和分离游离烯基硼酸的方法感兴趣,该方法可以补充我们的固相捕获方法。8 通常,(E)-1-烯基硼酸是通过相应末端炔烃的硼氢化反应获得的。然而,用于此目的的最常用方法存在化学和区域选择性问题。例如儿茶酚硼烷?它构成了实现这些转化的选择试剂,在炔丙基上不耐受 ace 或醚官能团。此外
  • Regio- and stereoselective synthesis of fluoroalkenes and fluoroalkadienes
    作者:Masanori Yoshida、Daisuke Ota、Tsuyoshi Fukuhara、Norihiko Yoneda、Shoji Hara
    DOI:10.1039/b108796g
    日期:2002.1.23
    (E)-Fluoroalkenes and (E,E)-fluoroalkadienes are synthesized stereoselectively from (E)-2-fluoro-1-iodoalk-1-enes by Pd-catalyzed cross-coupling reaction with organoboranes.
    (E)-氟代烯烃和(E,E)-氟代二烯烃可以通过钯催化的交叉偶联反应,从(E)-2-氟-1-碘代烯烃与有机硼试剂立体选择性地合成。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台